PSMA PET/CT阴性能否豁免新诊断前列腺癌患者的盆腔淋巴结清扫:以扩大盆腔淋巴结清扫病理为参照的系统评价与Meta分析
汇总敏感度58%、特异度95%、阳性预测值79%、阴性预测值87%;在高危患者中敏感度51%、特异度93%、阳性预测值73%、阴性预测值81%。结论:低LNI风险者高阴性预测值或可减少不必要PLND,高危患者阴性PSMA PET/CT不能替代分期性ePLND。
要点
- PSMA PET/CT检测LNI汇总敏感度58%、特异度95%,阴性预测值87%。
- 高危患者中阴性预测值81%,阴性PSMA PET/CT不能替代ePLND。
- LNI患病率5-40%时阳性预测值59%升至91%、阴性预测值99%降至84%。
核心结论
- PSMA PET/CT在原发淋巴结分期中具有较好准确性,低LNI风险男性中高阴性预测值或可减少不必要的PLND。
- 高危患者中阴性PSMA PET/CT不能替代分期性ePLND。
研究设计与样本
- 系统评价与Meta分析,检索PubMed/MEDLINE、Cochrane library's Central、EMBASE和Scopus,检索时间自建库至2021年5月。
- 主要结局为患者层面检测LNI的敏感度、特异度、阳性预测值和阴性预测值,次要结局为淋巴结层面的阴性预测值。
- 采用随机效应模型合并检出率,并按术前风险组进行预设亚组分析。
主要发现
- 患者层面PSMA PET/CT检测LNI的敏感度58%(95%CI 50-66%)、特异度95%(95%CI 93-97%)。
- 阳性预测值79%(95%CI 72-85%),阴性预测值87%(95%CI 84-89%),研究间总体存在中度异质性。
- 双变量分析中汇总受试者工作特征曲线下面积为84%(95%CI 81-87%)。
- 淋巴结层面PSMA PET的阴性预测值为97%(95%CI 96-99%)。
- 高危患者亚组敏感度51%、特异度93%、阳性预测值73%、阴性预测值81%。
关键数值与推荐
- LNI患病率在5-40%范围变化时,阳性预测值从59%升至91%,阴性预测值从99%降至84%。
- 仅以扩大盆腔淋巴结清扫(ePLND)作为参照标准的研究被纳入。
- 按术前风险组分层进行亚组分析以评估诊断准确性。
临床怎么用
- 对LNI低风险男性,PSMA PET/CT的高阴性预测值可能有助于减少不必要的盆腔淋巴结清扫。
- 对高危患者,阴性PSMA PET/CT结果不能替代分期性ePLND。
- 解读PSMA PET/CT结果时需结合LNI患病率,因阳性与阴性预测值随患病率变化而明显改变。
局限性
- 研究间总体存在中度异质性。
- 检索截止至2021年5月,未纳入此后发表的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The role of positron emission tomography/computed tomography (PET/CT) with prostate-specific membrane antigen (PSMA) in the primary staging for patients with prostate cancer (PCa) is still debated. OBJECTIVE: To analyze published studies reporting the accuracy of PSMA PET/CT for detecting lymph node invasion (LNI) at pelvic lymph node dissection (PLND). EVIDENCE ACQUISITION: A search of PubMed/MEDLINE, Cochrane library's Central, EMBASE and Scopus databases, from inception to May 2021, was conducted. The primary outcome was to evaluate the sensitivity, specificity, positive (PPV) and negative (NPV) predictive values of PSMA PET/CT in detecting LNI on a per-patient level. As a secondary outcome, NPV of PET PSMA was tested on a per-node-level analysis. Detection rates were pooled using random-effect models. Preplanned subgroup analyses tested the diagnostic accuracy after stratification for the preoperative risk group. PPV and NPV variation over LNI prevalence was evaluated. Only studies including extended PLND (ePLND) as the reference standard test were included. EVIDENCE SYNTHESIS: Twenty-seven studies, with a total of 2832 participants, were included in quantitative synthesis. The sensitivity, specificity, PPV, and NPV of PSMA PET/CT for LNI were, respectively, 58% (95% confidence interval [CI] 50-66%), 95% (95% CI 93-97%), 79% (95% CI 72-85%), and 87% (95% CI 84-89%), with overall moderate heterogeneity between studies. At bivariate analysis, the diagnostic accuracy of PSMA PET/CT estimated through summary receiver operating characteristic-derived area under the curve was 84% (95% CI 81-87%). On a per-node level, NPV of PET PSMA was 97% (95% CI 96-99%). At subgroup analyses, according to preoperative risk groups, sensitivity, specificity, PPV, and NPV were 51%, 93%, 73%, and 81%, respectively, in high-risk patients. Over the LNI prevalence range of 5-40%, PPV increased from 59% to 91%, while NPV decreased from 99% to 84%. CONCLUSIONS: PSMA PET/CT scan provides promising accuracy in the field of primary nodal staging for PCa. The high NPV in men with a lower risk of LNI might be clinically useful to reduce the number of unnecessary PLND procedures performed. Conversely, in high-risk patients, negative PSMA PET/CT cannot replace staging ePLND. PATIENT SUMMARY: In this systematic review and meta-analysis, we demonstrated that prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) scan may optimize the primary nodal staging and surgical management of prostate cancer patients candidate to radical prostatectomy. The high negative predictive value in men with a lower risk of lymph node invasion might be clinically useful for reducing the number of useless pelvic lymph node dissection (PLND) procedures performed. Conversely, in high-risk patients, negative PSMA PET/CT cannot allow avoiding of PLND.
引用
- Stabile A, Pellegrino A, Mazzone E, et al. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard. Eur Urol Oncol. 2021. PMID: 34538770. doi:10.1016/j.euo.2021.08.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。